Stock Events

Stock Events

TC BioPharm (Holdings) 

0
55
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
0Revenue
-6.8MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap680.62M
Allogene Therapeutics, Inc. works on allogeneic CAR T therapies for cancer, competing in the cell therapy space.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics AG is involved in gene editing and cell therapy for cancer, directly competing in the innovative treatment space.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, Inc. has a strong presence in cell therapy for cancer through its subsidiary Kite Pharma, making it a direct competitor.
Novartis
NVS
Mkt Cap304.1B
Novartis AG has approved CAR T-cell therapies in the market, making it a leading competitor in the cell therapy space.
Precigen
PGEN
Mkt Cap2.54B
Precigen, Inc. focuses on gene and cell therapies, including CAR T-cell therapies, competing in the same innovative treatment sector.

About

TC BIOPHARM (HLDGS) WTS
Show more...
CEO
Country
United Kingdom
ISIN
US87807D2027

Listings

OTC Link
US
TCBWF
STU
DE
T0U0.STU

0 Comments

Share your thoughts

FAQ

What is TC BioPharm (Holdings) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange TC BioPharm (Holdings) stocks are traded under the ticker T0U0.STU.
What is TC BioPharm (Holdings) revenue for the last year?▼
TC BioPharm (Holdings) revenue for the last year amounts to 0 EUR.
What is TC BioPharm (Holdings) net income for the last year?▼
T0U0.STU net income for the last year is -6.8M EUR.
In which sector is TC BioPharm (Holdings) located?▼
TC BioPharm (Holdings) operates in the Other sector.
When did TC BioPharm (Holdings) complete a stock split?▼
The last stock split for TC BioPharm (Holdings) was on December 15, 2023 with a ratio of 1:20.